Eli Lilly (LLY.N): ORforglipron showed clinically meaningful improvements over baseline in key cardiovascular risk factors.

2026-02-26

Eli Lilly (LLY.N): ORforglipron showed clinically meaningful improvements over baseline in key cardiovascular risk factors.